Pharma BD Deal Intelligence
Chiron Corporation / PathoGenesis Corporation
2000 · Acquisition/Merger · $700M · Complete
Announcement Sentiment
86
Strongly positive
Chiron agreed to pay $700M in cash for Seattle-based PathoGenesis. Deal added inhaled antibiotic TOBI (chronic CF lung infections) plus inhaled-antibiotic pipeline and ~275 staff. Anchored Chiron's anti-infectives franchise. Closed Sep 29, 2000.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 15yr post-close.
Key facts
- Announced Aug 14, 2000
- Closed Sep 29, 2000
- Deal value $700M
- Deal type Acquisition/Merger
- Therapeutic area Pseudomonas lung infection in cystic fibrosis
- Indications Pseudomonas lung infection in cystic fibrosis
- Key assets TOBI (tobramycin solution for inhalation)
- Mechanism Aminoglycoside antibiotic (inhaled)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals